- Report
- January 2026
- 185 Pages
Global
From €3445EUR$3,939USD£2,973GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2439EUR$2,789USD£2,105GBP
- Report
- September 2025
- 142 Pages
Global
From €3500EUR$4,287USD£3,126GBP
- Report
- October 2025
- 456 Pages
Global
From €4330EUR$4,950USD£3,736GBP
- Report
- May 2025
- 200 Pages
Global
From €2178EUR$2,490USD£1,879GBP
- Report
- January 2026
- 187 Pages
Global
From €3445EUR$3,939USD£2,973GBP
- Report
- August 2025
- 192 Pages
Global
From €3445EUR$3,939USD£2,973GBP
- Report
- August 2025
- 180 Pages
Global
From €3445EUR$3,939USD£2,973GBP
- Report
- August 2025
- 193 Pages
Global
From €3445EUR$3,939USD£2,973GBP
- Report
- February 2026
- 362 Pages
Global
From €5117EUR$5,850USD£4,415GBP
- Report
- February 2026
- 196 Pages
Global
From €5117EUR$5,850USD£4,415GBP
- Report
- August 2025
- 190 Pages
Global
From €3445EUR$3,939USD£2,973GBP
- Report
- September 2025
- 250 Pages
Global
From €3927EUR$4,490USD£3,389GBP
- Report
- September 2025
- 250 Pages
Global
From €3927EUR$4,490USD£3,389GBP
- Report
- April 2025
- 200 Pages
Global
From €3927EUR$4,490USD£3,389GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2624EUR$3,000USD£2,264GBP
- Report
- February 2026
- 381 Pages
Global
From €5117EUR$5,850USD£4,415GBP
- Report
- June 2025
- 400 Pages
Global
From €4329EUR$4,949USD£3,735GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2439EUR$2,789USD£2,105GBP
- Report
- August 2025
- 150 Pages
Global
From €3367EUR$3,850USD£2,906GBP
€4242EUR$4,850USD£3,660GBP

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors.
Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more